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Extended-spectrum b-lactamase (ESBL)-producing organisms are a global problem.No randomized
controlled trials have ever been performed to guide optimal treatment. However, in vitro studies and
observational studies strongly suggest that carbapenems (imipenemormeropenem) should be regarded as
drugs of choice for serious infections due to ESBL-producing organisms. Other b-lactam antibiotics
(cefepime, b-lactam/b-lactamase inhibitor combinations) are not suitable as ¢rst-line therapy.The
increasing frequencyof the association between quinolone resistance and ESBLproduction have greatly
limited the role of this class of antibiotic against ESBL producers.
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I N T R O D U C T I O N
Extended-spectrum b-lactamases (ESBLs) are plasmid-
mediated b-lactamases which have the ability to hydrolyze b-
lactam antibiotics containing an oxyimino group (e.g. ceftazi-
dime, ceftriaxone, cefotaxime or aztreonam). They have been
most commonly found in Klebsiella pneumoniae, but are being
increasingly found also in Escherichia coli, Proteus mirabilis and
other members of the Enterobacteriaceae. In contrast to the
inducible, chromosomally encoded b-lactamases produced by
organisms such as Enterobacter cloacae, the ESBLs are usually
susceptible to inactivation by compounds such as clavulanic
acid. In addition, the cephamycins (e.g. cefoxitin and cefote-
tan) are stable to hydrolysis by the ESBLs.
The vast majority of ESBLs are derivatives of TEM-1 (the
common plasmid-mediated b-lactamase of organisms such as
Escherichia coli) or SHV-1 (the common chromosomally
mediated b-lactamase of K. pneumoniae). TEM-1 and SHV-1
can inactivate ampicillin but not the third-generation cepha-
losporins; mutations in the genes encodingTEM-1 or SHV-1
extend the spectrum of activity of the b-lactamase so that
inactivation of third-generation cephalosporins and aztreo-
nam occurs. In many South American countries and in eastern
Europe, ESBLs of non-TEM and non-SHV lineage (e.g.
CTX-M-1 to CTX-M-6) are also prominent.TEM and SHV
derivatives are found in every inhabited continent, but non-
TEM, non-SHV ESBLs (e.g. the newly describedVEB-1 and
GES-1 ESBLs) are notable at the present time for the limited
geographic locations inwhich they have been isolated [1, 2].
Infections with ESBL-producing organisms are usually
hospital-acquired, especially in intensive care units. Nursing
homes may also be a reservoir [3]. Given the ecologic niche of
K. pneumoniae and other Enterobacteriaceae in the gastroin-
testinal tract, it is not surprising that common infections with
ESBL-producing organisms include urinary tract infections,
peritonitis, cholangitis and intra-abdominal abscesses. How-
ever, given the propensity for Gram-negative bacilli to colo-
nize the upper respiratory tract and skin of seriously ill
hospitalized patients, ESBL-producing organisms are also a
common cause of nosocomial pneumonia and central venous
line-related bacteremia. In hospitalized patients who have had
neurosurgical procedures, ESBL producers may also cause
meningitis.
On the other hand, it must be noted that for every patient
with a signi¢cant infection with an ESBL-producing organ-
ism, there are at least two patients with skin, urinary tract or
respiratory tract colonization, which does not require speci¢c
antimicrobial therapy. Identi¢cation of the colonized patient is
important, however, since these patients serve as a source of
infection for other patients in conditions where handwashing
and other basic infection control precautions are suboptimal
[4, 5].
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T H E R A P Y O F B A C T E R EM IA A N D O TH E R S E R IO U S
I N F EC T IO N S WIT H ES B L - P RO D U C IN G
O R G A N IS M S
No randomized controlled trials on therapy of infections
with ESBL-producing organisms have ever been performed,
and nor does it seem likely that such studies will be performed
in the near future. Therefore, recommendations for optimal
therapy of infections with ESBL-producing organisms are
based on studies of in vitro e¡ectiveness of antimicrobial
agents, small case series and large prospective observational
studies (Table1).
In vitro studies
In vitro, the carbapenems (imipenem and meropenem) and
the cephamycins have the most consistent activity against
ESBL-producing organisms, given their stability to hydroly-
sis by ESBLs. Indeed, published reports of carbapenem resis-
tance in organisms such as K. pneumoniae are exceedingly rare
[6, 7]. The plasmids harboring genes encoding ESBLs fre-
quently also contain genes encoding mechanisms of resistance
to aminoglycosides and trimethoprim^sulfamethoxazole.
Although there has been only one report of plasmid-mediated
quinolone resistance in K. pneumoniae [8], there is a strong
association between quinolone resistance and ESBL produc-
tion [9, 10]. The reason for this association is not well under-
stood, although it must be noted that patients with infections
with ESBL producers and patients with quinolone-resistant
isolates frequently share heavy prior antibiotic use (of both
third-generation cephalosporins and quinolones) [9]. Combi-
nations of b-lactam antibiotics with b-lactamase inhibitors are
usually active in vitro against organisms possessing a single
ESBL. However, in vitro resistance of ESBL-producing iso-
lates to such combinations is increasing alarmingly; in a study
of isolates from 35 intensive care units inwestern and southern
Europe, the percentage of ESBL-producing isolates resistant
to piperacillin^tazobactam rose from 31% in 1994 to 63% in
1997/1998 [10,11].
Cephalosporins
Di¡erent ESBLs vary in their ability to hydrolyze di¡erent
third-generation cephalosporins. Therefore, although an
ESBL-producing organism may have a ceftazidime MIC of
>256mg/L, the MIC for ceftriaxone or cefotaxime may be
less than 16mg/L (i.e. within the susceptible range, using cur-
rent NCCLS criteria) [12]. However, clinical outcome is poor
when third-generation cephalosporins are used to treat infec-
tions with ESBL-producing organisms, even in the presence
of apparent s`usceptibility' [13^16]. Third-generation cepha-
losporins should not be used to treat serious infections with
ESBL-producing organisms.
Even though cefepime exhibits more stability to hydrolysis
by ESBLs than the third-generation cephalosporins, positive
clinical results with the use of cefepime have not been forth-
coming [1, 17]. In common with third-generation cephalo-
sporins, MICs for cefepime rise substantially when the
inoculum of infecting organisms rises. In vitro synergy may
be achievable between cefepime and amikacin against ESBL-
producing organisms [17]. Cefepime should not be used as
¢rst-line therapy against ESBL-producing organisms; when
it is used, it should be used in high dosage, preferably in com-
binationwith an aminoglycoside.
Based on in vitro studies, the cephamycins appear an attrac-
tive option for use against ESBL-producing organisms. How-
ever, published clinical experience with these drugs is almost
completely lacking.The only reports describe in vivo selection
of porin-de¢cient mutants during therapy [18^20]. In addi-
tion, combined cephamycin and carbapenem resistance in K.
pneumoniae has been observed in the setting of widespread
cephamycin use in response to an outbreak of infection with
ESBL-producing organisms [6]. Until positive published
clinical experience with cephamycins appears, these drugs
must be regarded as second-line therapy for infections with
Table 1 Treatment recommendations for infections caused by organisms producing extended-spectrum b-lactamases (ESBLs)
Type of infection First-line therapy Second-line therapy
Bacteremia Carbapenema (imipenem or meropenem) Cipro¯oxacin
Nosocomial pneumonia Carbapenem (imipenem or meropenem) Cipro¯oxacin
Intra-abdominal infection Carbapenema (imipenem or meropenem) Cipro¯oxacin
Urinary tract infection Cipro¯oxacin Amoxycillin±clavulanate
Meningitis Meropenema Addition of polymyxin B
aRemoval of central venous lines, drainage of collections and removal of neurosurgical hardware is important for optimal outcome of these
infections.
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ESBL-producing organisms. In general, cefotetan has lower
MICs than cefoxitin, and should be used preferentially.
b-Lactam/b-lactamase inhibitor combinations
As with the cephalosporins, combinations of b-lactam with
b-lactamase inhibitor (e.g. ticarcillin^clavulanate or pipera-
cillin^tazobactam) are also subject to rising MICs as inocu-
lum rises. In addition, hyperproduction of b-lactamases or the
combination of b-lactamase production and porin loss can
also lead to reduction in activity of b-lactam/b-lactamase
inhibitor combinations. Published clinical experience with
use of these antibiotics for serious infections due to ESBL-
producing organisms has been limited, but observed mortal-
ity rates have been>50% [13, 21, 22]. Although the combina-
tion of cephalosporins and b-lactamase inhibitors is a
theoretically attractive option, there is no published experi-
ence with this therapy, and it is possible that the same limita-
tions will apply as seen with penicillins and b-lactamase
inhibitors.
Carbapenems
Carbapenems should be regarded as the drugs of choice for
serious infections with ESBL-producing organisms (Table 1).
The basis for this statement is not just the almost uniform in
vitro susceptibility but also increasingly extensive clinical
experience. Published experience now amounts to more than
100 patients. Meyer [23], in his account of a prolonged out-
break of infections due to ESBL-producing organisms, was
among the ¢rst to suggest that outcome was superior with
imipenem. More recently, a large prospective, multicountry
study ofK. pneumoniae bacteremia has shown that mortality in
patients with blood culture-positive, ESBL-producing organ-
isms was less than 10% when patients received either imipe-
nemormeropenem [13].
The choice between imipenem and meropenem is di¤cult.
Published experience is greatest with imipenem, butMICs for
meropenem are slightly lower than for imipenem. Invitro stu-
dies with a newcarbapenem capable of once-daily administra-
tion show that it shares the excellent activity against ESBL-
producing organisms of imipenem andmeropenem [24].
Meropenem is the drug of choice in treatment of nosoco-
mial meningitis due to ESBL-producing organisms, since it is
likely to be less prone to neurologic side-e¡ects than imipe-
nem in patients with underlying central nervous system
(CNS) disease. Removal of neurosurgical hardware is manda-
tory in treatment of CNS shunt infections, and intrathecal
polymyxin B should also be considered [25].
There is no evidence that combination therapy with a car-
bapenem and antibiotics of other classes is superior to use of a
carbapenem alone. Synergy has been exhibited in some but
not all studies [17, 26]. However, anecdotal experience is that
many clinicians use a combination of a carbapenem and an
aminoglycoside such as amikacin in severely ill patients with
documented infections due to ESBL-producing organisms.
Other drug classes
The use of aminoglycosides for serious infections due to
ESBL-producing organisms should probably be limited to
combination therapy with b-lactam antibiotics. Quinolones
may be regarded as the treatment of choice for less severe infec-
tions with ESBL-producing organisms, such as urinary tract
infection. Unfortunately, increasing in vitro resistance to qui-
nolones in isolates which are also ESBL producers [9, 10] will
limit the role of these antibiotics in the treatment of infections
due to ESBL-producing organisms in the future. In general,
newer quinolones are unlikely to provide additional bene¢ts
over cipro£oxacin.
S U M M A R Y
The detection in the clinical microbiology laboratory of
ESBL production by Enterobacteriaceae is of great impor-
tance for at least three reasons. First, horizontal transfer of
ESBL-producing organisms (often by the hands of medical
and nursing sta¡) is a frequent occurrence but can be limited
by use of contact isolation. Such isolation can be triggered by
the designation of the organism as an ESBL producer. Second,
serious infections with ESBL-producing organisms should
not be treatedwith cephalosporins.Treatment failure has often
been observed. Finally, a treatment of choice is emerging for
such serious infections. Carbapenems (e.g. imipenemor mero-
penem) have been shown to be associated with the lowest
mortality of any drug class when used against infections with
ESBL-producing organisms.
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